dk.jpg

Bethesda Neurology

Clinical Trials

Dr. Katz is the DC-region primary investigator enrolling patients who have suffered non-arteritic anterior ischemic optic neuropathy (NAION) more than one year prior, with the hope of regenerating the damaged optic nerve fibers.  The trial is call REGENERA.

Dr. Katz is the DC regional principal investigator testing the first novel treatment for Leber's Hereditary Optic Neuropathy, a genetic disorder that causes bilateral optic nerve damage in young patients.

Dr. Katz was the DC-region primary investigator for an NIH sponsored US and Canadian clinical trial: Idiopathic Hypertension Treatment Trial (IIHTT).  IIH, also known as pseudotumor cerebri (PTC), is a disorder of elevated intracranial pressure of unknown cause.  The incidence is 225 new cases each year per 100,000 overweight women of childbearing age; it's incidence is rising in parallel with the obesity epidemic in developed countries.  It affect over 100.00 Americans.

For more information please review the website: www.nordicclinicaltrials.com